These agents inhibited MDM2–p53 PPI with IC50 values in the range of 0.001–0.05 μM, resulting in effective blockage of human lung cancer NCI-H460 cell proliferation with wild-type p53 (GI50 < 0.1 μM, MTT assay). The gene discussed is TP53; the disease is lung cancer.